Breakthrough mRNA Vaccine for Over-60s Gets Approval: New Hope Against RSV
2025-02-28
MSN
In a significant development, a new vaccine using mRNA technology, similar to the Covid vaccine, has been approved for use in individuals over 60. Manufactured by US pharmaceutical giant Moderna, this vaccine has shown remarkable efficacy in reducing the risk of severe illness from respiratory syncytial virus (RSV), offering new hope for protection against this common and potentially serious illness, particularly among older adults, and highlighting the benefits of mRNA technology in vaccine development and disease prevention.
